Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alyssa H Cull

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Blood|May 22, 2025
Of donors and dynamicsAlyssa H Cull, David G Kent
Journal of Leukocyte Biology|June 10, 2017
Success in bone marrow failure? Novel therapeutic directions based on the immune environment of myelodysplastic syndromesAlyssa H Cull, Michael J Rauh
Blood|June 21, 2024
Emerging genetic technologies informing personalized medicine in Shwachman-Diamond syndrome and other inherited BMF disordersAlyssa H Cull, David G Kent, Alan J Warren
Frontiers in Immunology|July 29, 2021
Exploiting Single-Cell Tools in Gene and Cell TherapyDaniel Bode, Alyssa H Cull, Juan A Rubio-Lara, et al.
Experimental Hematology|August 23, 2017
Tet2 restrains inflammatory gene expression in macrophagesAlyssa H Cull, Brooke Snetsinger, Rena Buckstein, et al.
Nature Medicine|November 17, 2023
Clonal selection of hematopoietic stem cells after gene therapy for sickle cell diseaseMichael Spencer Chapman, Alyssa H Cull, Marioara F Ciuculescu, et al.
Experimental Hematology|May 19, 2024
Increased CXCL10 (IP-10) is associated with advanced myeloproliferative neoplasms and its loss dampens erythrocytosis in mouse modelsMiriam Belmonte, Lilia Cabrera-Cosme, Nina F Øbro, et al.
EMBO Reports|August 16, 2022
Identification and characterization of in vitro expanded hematopoietic stem cellsJames L C Che, Daniel Bode, Iwo Kucinski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2017
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117Mikkael A Sekeres, Megan Othus, Alan F List, et al.
Cell Reports|December 25, 2025
Low-input proteomics identifies vWF as a negative regulator of Tet2 mutant hematopoietic stem cell expansionMaria Jassinskaja, Daniel Bode, Monika Gonka, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Blood|May 22, 2025
Of donors and dynamicsAlyssa H Cull, David G Kent
Journal of Leukocyte Biology|June 10, 2017
Success in bone marrow failure? Novel therapeutic directions based on the immune environment of myelodysplastic syndromesAlyssa H Cull, Michael J Rauh
Blood|June 21, 2024
Emerging genetic technologies informing personalized medicine in Shwachman-Diamond syndrome and other inherited BMF disordersAlyssa H Cull, David G Kent, Alan J Warren
Frontiers in Immunology|July 29, 2021
Exploiting Single-Cell Tools in Gene and Cell TherapyDaniel Bode, Alyssa H Cull, Juan A Rubio-Lara, et al.
Experimental Hematology|August 23, 2017
Tet2 restrains inflammatory gene expression in macrophagesAlyssa H Cull, Brooke Snetsinger, Rena Buckstein, et al.
Nature Medicine|November 17, 2023
Clonal selection of hematopoietic stem cells after gene therapy for sickle cell diseaseMichael Spencer Chapman, Alyssa H Cull, Marioara F Ciuculescu, et al.
Experimental Hematology|May 19, 2024
Increased CXCL10 (IP-10) is associated with advanced myeloproliferative neoplasms and its loss dampens erythrocytosis in mouse modelsMiriam Belmonte, Lilia Cabrera-Cosme, Nina F Øbro, et al.
EMBO Reports|August 16, 2022
Identification and characterization of in vitro expanded hematopoietic stem cellsJames L C Che, Daniel Bode, Iwo Kucinski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2017
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117Mikkael A Sekeres, Megan Othus, Alan F List, et al.
Cell Reports|December 25, 2025
Low-input proteomics identifies vWF as a negative regulator of Tet2 mutant hematopoietic stem cell expansionMaria Jassinskaja, Daniel Bode, Monika Gonka, et al.
Pageof 1